Sunday, Apr 28 2024 | Time 11:11 Hrs(IST)
image
Business Economy


IIL to invest Rs 75 crore to expand its Karkapatla Plant in Telangana

IIL to invest Rs 75 crore to expand its Karkapatla Plant in Telangana

Hyderabad, Jun 24 (UNI) Indian Immunologicals Limited (IIL), a leading biologicals company, on Monday announced the ground-breaking of a new Sterile Filling Facility (SFF) at its manufacturing plant in Phase III of Genome Valle in Karkapatla of Telangana.



With Rs 75 crore investment in the upcoming SFF, Indian Immunologicals Limited expects to increase its capacity to supply lifesaving vaccines such as the Anti Rabies Vaccine (ARV) – Abhayrab™.



The new state-of-the-art facility expected to be ready by later next year. The SFF is equipped with hi-end filling equipment from the world’s best manufacturers, in line with the requirements of the nature of work handled at the plant, a company statement here said.



Speaking on the occasion, Dr K Anand Kumar, Managing Director – Indian Immunologicals Limited said, “IIL has a long history of supplying vaccines critical to public health. We are constantly striving to make the vaccines affordable and accessible to reach the benefits of preventive healthcare to maximum number of people.

The expansion at Karkapatla plant is in line with our mission and will help meet the growing requirements of critical vaccines”.



Various reports in the past few months indicate that several states in the country have reported shortages of ARV, due to a combination of factors including growing demand, imperfect demand signal, and supply disruptions. Reports indicated that the shortages sometime extend to the tune of 60-80 per cent.



“Currently there are reports of shortages of anti-rabies vaccine in the country. Investment in a new sterile filling facility shows that IIL is committed to expanding manufacturing capacity to meet unmet public health needs in India. With supply from this facility, IIL will continue to be the largest rabies vaccine manufacturer in the country,” said Dr Prasanna Deshpande, Deputy Managing Director, IIL.



IIL has 4 manufacturing facilities at various locations – Karkapatla, Telangana – Human Vaccines & Animal Health Formulations, Ooty, Tamil Nadu – Anti Rabies production unit; Hyderabad, Telangana – Human Biologicals Unit (Gachibowli) and animal vaccines unit, Dargaville, New Zealand - New Bovine Serum.

IIL exports various Human and animal vaccines to over 50 countries and currently employs around 1,300 people, the release said.

UNI VV CS 1311

More News
IDFC First Bank Q4 net profit plunges 10 pc to Rs 724 crore

IDFC First Bank Q4 net profit plunges 10 pc to Rs 724 crore

27 Apr 2024 | 11:11 PM

New Delhi, April 27 (UNI) IDFC FIRST Bank on Saturday reported 9.83% year-on-year decline in net profit for January-March quarter (Q4) of financial year 2023-24.

see more..

ICICI Bank profit in Q4 jumps 17 pc to Rs 10,707 crore

27 Apr 2024 | 9:11 PM

New Delhi, April 27 (UNI) Private lender ICICI Bank on Saturday reported 17.38% year-on-year jump in standalone net profit at Rs 10,707.53 crore for January-March quarter (Q4) of the financial year 2023-24.

see more..

Kottayam-Kochi Rubber Market Rates

27 Apr 2024 | 4:26 PM

Kottayam, April 27 (UNI) Following were the Rubber Market rates announced by the Rubber Board here today per quintal.

see more..

Horizon Industrial Parks announces ground-breaking of its 2nd logistics park in Pune

27 Apr 2024 | 1:50 PM

Pune, April 27 (UNI) Horizon Industrial Parks, a portfolio of Grade A logistics parks in India owned by Blackstone Real Estate funds, has announced the groundbreaking of its second logistics park in Pune, Chakan.

see more..
Rupee falls 2 paise against USD

Rupee falls 2 paise against USD

26 Apr 2024 | 5:28 PM

Mumbai, April 26 (UNI) The Rupee on Friday eased 2 paise to close at 83.35 against the USD on rising demand for US Dollar by bankers and importers, dealers at the Foreign exchange said.

see more..
image